NuVasive To Acquire Ellipse Technologies

| Printer friendly version

In a recent press release, San Diego, California-based NuVasive, Inc. nuvasive-logo-2005announced that it will acquire Ellipse Technologies, Inc. (“Ellipse”), a privately held medical technology company based in Aliso Viejo, California.  According to its website, NuVasive is the third largest medical device company in the global spine industry and is dedicated to innovation and development focused on minimally disruptive surgical products and procedures for the spine.  Ellipse describes itself as an innovative company dedicated to the design, development, and successful commercialization of non-invasively Ellipseadjustable, remote controlled implants for a broad spectrum of spinal and orthopedic applications.

The press release states that the acquisition builds on NuVasive’s reputation as the leading technology provider for spine procedure solutions by adding a “highly regarded, disruptive technology platform.”  Specifically, a Medical Device and Diagnostic Industry article reports that the acquisition strategically adds two of Ellipse’s main products to NuVasive’s product portfolio – MAGEC and PRECICE – products that will help boost NuVasive’s magecinternational footprint, since 37% of Ellipse’s 2015 revenue came from overseas.  According to Ellipse, MAGEC (shown to the right) is a non-invasively adjustable growing rod used to brace the spine during growth to minimize the progression of scoliosis, and PRECICE is an adjustable intramedullary nail used for limb lengthening of the femur and tibia.

In connection with the acquisition, Gregory T. Lucier, Chairman and CEO of NuVasive, stated:

NuVasive remains committed to adult deformity through our Integrated Global Alignment (iGA™) platform, and the acquisition of Ellipse will aggressively insert NuVasive into early onset and idiopathic scoliosis, an important and attractive part of the spinal deformity market for NuVasive where we have tremendous opportunities for accelerated growth.

Edmund J. Roschak, President and CEO of Ellipse, said:

Joining forces with NuVasive not only validates the promise of our technology, but provides us with the scale and resources necessary to realize our full potential.

The press release notes that the Boards of Directors of both companies unanimously approved the terms of the acquisition, which include a $380 million upfront cash payment as well as a potential $30 million milestone payable in 2017.  The transaction is expected to close by the end of February 2016, subject to customary closing conditions and regulatory approvals.

Grant McAdams
Grant McAdams is an associate in the firm's San Francisco office. His practice focuses on patent law. Mr. McAdams received his law degree from UCLA School of Law, where he was a member of the Journal of International Law and Foreign Affairs. He received his bachelors degree in biomedical engineering from Michigan Technological University. Mr. McAdams joined the firm in 2014.
Click here to read full bio
View all posts published by Grant McAdams »

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.